Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment
| Autor: | Françoise Berger, Evelyne Callet-Bauchu, Josette Brière, Alexandra Traverse-Glehen, Nicolas Munoz-Bongrand, Pauline Brice, Julien Lenglet, Nicolas Mounier, Claire Benet, Catherine Thieblemont, Lucile Baseggio, Catherine Traulle, Maria-Elena Noguera, Martine Ffrench, Gilles Salles, Pascale Felman, Sandy Amorin, Bertrand Coiffier |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lymphocytosis Long term follow up Lymphocyte medicine.medical_treatment Splenectomy Gastroenterology Immunophenotyping Risk Factors Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Splenic marginal zone lymphoma Aged Neoplasm Staging Aged 80 and over business.industry Splenic Neoplasms Retrospective cohort study Hematology Hepatitis C Lymphoma B-Cell Marginal Zone Middle Aged medicine.disease Prognosis Surgery First line treatment medicine.anatomical_structure Treatment Outcome Oncology Female medicine.symptom Neoplasm Grading business Follow-Up Studies |
| Zdroj: | Leukemialymphoma. 55(8) |
| ISSN: | 1029-2403 |
| Popis: | Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative patients with SMZL were treated by splenectomy as first-line treatment. At 6 months, all patients but three recovered from all cytopenias. The median lymphocyte count at 6 months and 1 year was 11.51 × 10(9)/L and 6.9 × 10(9)/L, respectively. Median progression-free survival (PFS) was 8.25 years. The 5-year and 10-year overall survival (OS) rates were 84% and 67%, respectively. Histological transformation occurred in 11% of patients, and was the only parameter significantly associated with a shorter time to progression (p = 0.0001). Significant prognostic factors for OS were age (p = 0.0356) and histological transformation (p = 0.0312). In this large retrospective cohort, we confirmed that splenectomy as first-line treatment in patients with SMZL corrected cytopenias and lymphocytosis within the first year and was associated with a good PFS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|